Compare, Analyse NEULAND LABS with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the worlds leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industrys broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NEULAND LABS   MYLAN
EQUITY SHARE DATA
    NEULAND LABS
Mar-20
MYLAN
Dec-18
NEULAND LABS/
MYLAN
5-Yr Chart
Click to enlarge
High Rs7543,493-   
Low Rs2471,923-   
Sales per share (Unadj.) Rs594.51,607.2-  
Earnings per share (Unadj.) Rs12.643.6-  
Cash flow per share (Unadj.) Rs37.0344.6-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs553.41,738.7-  
Shares outstanding (eoy) m12.83514.50-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.81.7 50.0%   
Avg P/E ratio x39.662.0 63.9%  
P/CF ratio (eoy) x13.57.9 172.1%  
Price / Book Value ratio x0.91.6 58.1%  
Dividend payout %15.80-   
Avg Mkt Cap Rs m6,4211,393,123 0.5%   
No. of employees `0001.335.0 3.7%   
Total wages/salary Rs m1,2360-   
Avg. sales/employee Rs Th5,949.423,626.3 25.2%   
Avg. wages/employee Rs Th963.80-   
Avg. net profit/employee Rs Th126.4641.6 19.7%   
INCOME DATA
Net Sales Rs m7,627826,919 0.9%  
Other income Rs m390-   
Total revenues Rs m7,666826,919 0.9%   
Gross profit Rs m1,019213,976 0.5%  
Depreciation Rs m313154,832 0.2%   
Interest Rs m21639,772 0.5%   
Profit before tax Rs m52919,372 2.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m367-3,082 -11.9%   
Profit after tax Rs m16222,454 0.7%  
Gross profit margin %13.425.9 51.6%  
Effective tax rate %69.4-15.9 -436.1%   
Net profit margin %2.12.7 78.3%  
BALANCE SHEET DATA
Current assets Rs m5,152461,751 1.1%   
Current liabilities Rs m3,576336,667 1.1%   
Net working cap to sales %20.715.1 136.6%  
Current ratio x1.41.4 105.0%  
Inventory Days Days10584 125.7%  
Debtors Days Days9193 97.4%  
Net fixed assets Rs m3,969160,409 2.5%   
Share capital Rs m129440 29.3%   
"Free" reserves Rs m6,9710-   
Net worth Rs m7,100894,576 0.8%   
Long term debt Rs m774965,534 0.1%   
Total assets Rs m12,3102,399,599 0.5%  
Interest coverage x3.51.5 232.2%   
Debt to equity ratio x0.11.1 10.1%  
Sales to assets ratio x0.60.3 179.8%   
Return on assets %3.12.6 118.4%  
Return on equity %2.32.5 91.0%  
Return on capital %9.53.2 297.6%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m3,5940-   
CASH FLOW
From Operations Rs m573171,834 0.3%  
From Investments Rs m-487-88,819 0.5%  
From Financial Activity Rs m-55-80,050 0.1%  
Net Cashflow Rs m331,424 2.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 73.38 Rs / USD

Compare NEULAND LABS With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare NEULAND LABS With: FULFORD INDIA  CADILA HEALTHCARE  WYETH  DIVIS LABORATORIES  J.B.CHEMICALS  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views On News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

Why Did Alembic Pharma Shares Fall Today? (Views On News)

May 5, 2021

Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.

More Views on News

Most Popular

The Next Smallcap Winners (Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps? (Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony? (Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks (Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

FREE Event: Discover Your First Stock for a Potential Rs 7 Crore in Long-term Wealth
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

NEULAND LABS SHARE PRICE


May 12, 2021 03:36 PM

TRACK NEULAND LABS

  • Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NEULAND LABS

NEULAND LABS 5-YR ANALYSIS

COMPARE NEULAND LABS WITH

FEATURED VIDEOS

The 'Big' Money is in this 'Small' Detail

Stability, Quality or Green Stocks for 2021?

Market Crash: Picture Abhi Baaki Hai?

It's a Great Time to Buy Gold

More Featured Videos

MARKET STATS